Cargando…

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions

Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and immunotherapy seems to be a promising approach for treating ESCC. This comprehensive review article summarizes the current state of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Mengjie, Hu, Yujie, Lin, Gang, Chen, Chao, Li, Huafeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261849/
https://www.ncbi.nlm.nih.gov/pubmed/37325652
http://dx.doi.org/10.3389/fimmu.2023.1177085
_version_ 1785057957570936832
author Jiang, Mengjie
Hu, Yujie
Lin, Gang
Chen, Chao
Li, Huafeng
author_facet Jiang, Mengjie
Hu, Yujie
Lin, Gang
Chen, Chao
Li, Huafeng
author_sort Jiang, Mengjie
collection PubMed
description Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and immunotherapy seems to be a promising approach for treating ESCC. This comprehensive review article summarizes the current state of combination of radiotherapy and immunotherapy in locally advanced/metastatic ESCC, delineates the clinical trials that merit attention, and outlines unresolved issues and future research directions in this field. The clinical trial findings suggest that radio-immunotherapy combination may improve tumor response and overall survival with manageable side effects, highlighting the importance of patient selection and the necessity for further research to optimize treatment strategies. Issues such as irradiation dosage, fractionation regimen, irradiation site and technique of radiotherapy, as well as the timing, sequence and duration of combination therapy will all affect treatment outcomes, justifying further in-depth investigation.
format Online
Article
Text
id pubmed-10261849
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102618492023-06-15 Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions Jiang, Mengjie Hu, Yujie Lin, Gang Chen, Chao Li, Huafeng Front Immunol Immunology Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and immunotherapy seems to be a promising approach for treating ESCC. This comprehensive review article summarizes the current state of combination of radiotherapy and immunotherapy in locally advanced/metastatic ESCC, delineates the clinical trials that merit attention, and outlines unresolved issues and future research directions in this field. The clinical trial findings suggest that radio-immunotherapy combination may improve tumor response and overall survival with manageable side effects, highlighting the importance of patient selection and the necessity for further research to optimize treatment strategies. Issues such as irradiation dosage, fractionation regimen, irradiation site and technique of radiotherapy, as well as the timing, sequence and duration of combination therapy will all affect treatment outcomes, justifying further in-depth investigation. Frontiers Media S.A. 2023-05-30 /pmc/articles/PMC10261849/ /pubmed/37325652 http://dx.doi.org/10.3389/fimmu.2023.1177085 Text en Copyright © 2023 Jiang, Hu, Lin, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jiang, Mengjie
Hu, Yujie
Lin, Gang
Chen, Chao
Li, Huafeng
Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
title Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
title_full Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
title_fullStr Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
title_full_unstemmed Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
title_short Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
title_sort radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261849/
https://www.ncbi.nlm.nih.gov/pubmed/37325652
http://dx.doi.org/10.3389/fimmu.2023.1177085
work_keys_str_mv AT jiangmengjie radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections
AT huyujie radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections
AT lingang radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections
AT chenchao radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections
AT lihuafeng radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections